Ojwang J O, Hampel A, Looney D J, Wong-Staal F, Rappaport J
Department of Medicine, University of California, San Diego, La Jolla 92093-0665.
Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10802-6. doi: 10.1073/pnas.89.22.10802.
Ribozymes are RNAs that possess the dual properties of RNA sequence-specific recognition, analogous to conventional antisense molecules, and RNA substrate destruction via site-specific cleavage. The cleavage reaction is catalytic in that more than one substrate molecule is processed per ribozyme molecule. We have designed a hairpin ribozyme that cleaves human immunodeficiency virus type 1 (HIV-1) RNA in the leader sequence (at nucleotides +111/112 relative to the transcription initiation site). The ribozyme was tested in vitro and gave efficient and specific cleavage of RNA containing the leader sequence. To test the antiviral efficacy of this ribozyme, we have cotransfected into HeLa cells HIV-1 proviral DNA and a plasmid expressing the ribozyme from the human beta-actin promoter. HIV-1 expression was inhibited as measured by p24 antigen levels and reduced Tat activity. The antiviral effect of the ribozyme appears to be specific and results from directed RNA cleavage; activity requires both a target sequence and a functional RNA catalytic center. These results suggest that this HIV-1-directed hairpin ribozyme may be useful as a therapeutic agent.
核酶是一类RNA,它们具有双重特性:一方面类似于传统反义分子,能对RNA序列进行特异性识别;另一方面能通过位点特异性切割来破坏RNA底物。切割反应具有催化性,即每个核酶分子能处理不止一个底物分子。我们设计了一种发夹状核酶,它能切割人免疫缺陷病毒1型(HIV-1)前导序列中的RNA(相对于转录起始位点的核苷酸+111/112处)。该核酶在体外进行了测试,对含有前导序列的RNA能进行高效且特异性的切割。为了测试这种核酶的抗病毒效果,我们将HIV-1前病毒DNA和一个从人β-肌动蛋白启动子表达核酶的质粒共转染到HeLa细胞中。通过p24抗原水平测定以及Tat活性降低来衡量,HIV-1的表达受到了抑制。核酶的抗病毒作用似乎具有特异性,是由定向RNA切割导致的;其活性既需要靶序列,也需要功能性的RNA催化中心。这些结果表明,这种针对HIV-1的发夹状核酶可能作为一种治疗剂具有应用价值。